Our Pipeline

Novel disease-modifying therapies

We believe our approach can be applied to a broad array of severe genetic diseases, including genetic conditions affecting the central nervous system (CNS), eye, liver and kidney. We are initially pursuing monogenic diseases, with a focus on dominant loss-of-function, or haploinsufficient, diseases. We are prioritizing diseases with significant unmet medical need to bring new treatments forward as rapidly as possible.

Pipeline Pipeline